Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. / (Record no. 1182)

MARC details
000 -LEADER
fixed length control field 03620naa a22004697i 4500
001 - CONTROL NUMBER
control field UMUN-OA-20261005-MLS-040
003 - CONTROL NUMBER IDENTIFIER
control field local
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20261005174904.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr||||||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 261005s2023 xx o u000 0 eng d
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1038/s41392-023-01521-5
Source of number or code doi
035 ## - SYSTEM CONTROL NUMBER
System control number (local)EuropePMC:PMC10435569
040 ## - CATALOGING SOURCE
Original cataloging agency local
Language of cataloging eng
Transcribing agency local
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title eng
100 0# - MAIN ENTRY--PERSONAL NAME
Personal name Lu Tang
Relator term author.
245 10 - TITLE STATEMENT
Title Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. /
Statement of responsibility, etc. Lu Tang; Zhongpei Huang; Heng Mei [and others].
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture [Place of publication not identified] :
Name of producer, publisher, distributor, manufacturer Nature Publishing Group,
Date of production, publication, distribution, manufacture, or copyright notice 2023.
300 ## - PHYSICAL DESCRIPTION
Extent 1 online resource (1 article).
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
500 ## - GENERAL NOTE
General note Publication type: Review article.
500 ## - GENERAL NOTE
General note Linked open-access copy: published version.
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open access; no subscription required for the linked open-access version.
Standardized terminology for access restriction Unrestricted online access
Source of term star
520 3# - SUMMARY, ETC.
Summary, etc. The immune-cell origin of hematologic malignancies provides a unique avenue for the understanding of both the mechanisms of immune responsiveness and immune escape, which has accelerated the progress of immunotherapy. Several categories of immunotherapies have been developed and are being further evaluated in clinical trials for the treatment of blood cancers, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies. These immunotherapies have shown the potential to induce long-term remission in refractory or relapsed patients and have led to a paradigm shift in cancer treatment with great clinical success. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed. To provide clinicians with timely information on these revolutionary therapeutic approaches, the comprehensive review provides historical perspectives on the applications and clinical considerations of the immunotherapy. Here, we first outline the recent advances that have been made in the understanding of the various categories of immunotherapies in the treatment of hematologic malignancies. We further discuss the specific mechanisms of action, summarize the clinical trials and outcomes of immunotherapies in hematologic malignancies, as well as the adverse effects and toxicity management and then provide novel insights into challenges and future directions.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons Attribution. See the linked licence for the applicable terms.
Uniform Resource Identifier <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a>
546 ## - LANGUAGE NOTE
Language note In English.
588 0# - SOURCE OF DESCRIPTION NOTE
Source of description note Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 ## - LOCAL NOTE (RLIN)
Local note Course allocation: B. Sc. Medical Laboratory Science.
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term B. Sc. Medical Laboratory Science
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term UMUN open access collection
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term hematology
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term Review articles.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Zhongpei Huang
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Heng Mei
Relator term author.
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Yu Hu
Relator term author.
773 0# - HOST ITEM ENTRY
Title Signal transduction and targeted therapy
Related parts Vol. 8, no. 1, (2023), pages/article 306
International Standard Serial Number 2095-9907
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://europepmc.org/articles/PMC10435569">https://europepmc.org/articles/PMC10435569</a>
Link text Read open-access publication
Public note Open access.
Access status 0
884 ## - DESCRIPTION CONVERSION INFORMATION
Conversion process Course selection and automated MARC21 enrichment from Europe PMC metadata.
Conversion date 20261005
Identifier of source metadata https://europepmc.org/articles/PMC10435569
Conversion agency local
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Suppress in OPAC No

No items available.